About GigaGen
GigaGen is a company based in San Francisco (United States) founded in 2011 was acquired by Grifols in March 2021. GigaGen has raised $36.13 million across 19 funding rounds from investors including NIH, Grifols and HHS. The company has 36 employees as of December 31, 2022. GigaGen offers products and services including GIGA-564 and GIGA-2339. GigaGen operates in a competitive market with competitors including Sana Biotechnology, TScan Therapeutics, Janux Therapeutics, Carisma Therapeutics and Kronos Bio, among others.
- Headquarter San Francisco, United States
- Employees 36 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gigagen Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GigaGen
GigaGen offers a comprehensive portfolio of products and services, including GIGA-564 and GIGA-2339.
Targets CTLA-4 for treating advanced solid tumors with improved efficacy.
Therapy for Hepatitis B virus to neutralize infection and aid treatment.
People of GigaGen
Unlock access to complete
Funding Insights of GigaGen
GigaGen has successfully raised a total of $36.13M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $3 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GigaGen
GigaGen has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include NIH, Grifols and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked | |
|
Energy sources and policies are managed by the DOE.
|
Locked | Locked | Locked |
Investor details for GigaGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GigaGen
Investment portfolio details for GigaGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GigaGen
Detailed financials for GigaGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gigagen Comparisons
Peer comparison for GigaGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GigaGen
GigaGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, TScan Therapeutics, Janux Therapeutics, Carisma Therapeutics and Kronos Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of GigaGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gigagen
Complete news archive for GigaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GigaGen
GigaGen was founded in 2011.
GigaGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
GigaGen is a funded company, having raised a total of $36.13M across 19 funding rounds to date.
As of Dec 31, 2022, the latest employee count at GigaGen is 36.
Founded in 2011 and based in San Francisco, United States, GigaGen operates in the biotechnology sector. T-cell and antibody-based therapeutics are developed using a high-throughput platform that incorporates microfluidics, bioinformatics, next-generation sequencing, and genetic engineering. Full-length natively paired antibodies and T-cell receptors are produced from single primary B or T cells, with integration of clonal identity, function, and target binding data.
GigaGen's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
GigaGen offers GIGA-564 and GIGA-2339.
GigaGen has 6 investors. Key investors include NIH, Grifols, HHS, DOE, and National Science Foundation.